Table 2.

Cox models with age, stage, MYCN amplification, and the expression of EPHB6, EFNB2, and EFNB3

Model	Variable	HR (95% CI)	P	Variable	HR (95% CI)	P
A1	Age*	5.31 (0.66–42.64)	0.116	EPHB6§	0.09 (0.02–0.54)	0.009
A2	Stage†	8.58 (1.06–69.40)	0.044	EPHB6	0.11 (0.01–0.84)	0.034
A3	MYCN‡	4.03 (1.20–13.50)	0.024	EPHB6	0.10 (0.01–0.80)	0.030
B1	Age	3.14 (0.35–28.07)	0.306	EFNB2§	0.20 (0.07–0.60)	0.004
B2	Stage	6.7 (0.79–56.50)	0.080	EFNB2	0.24 (0.09–0.69)	0.008
B3	MYCN	1.56 (0.28–8.76)	0.615	EFNB2	0.20 (0.04–0.90)	0.036
C1	Age	5.33 (0.67–42.38)	0.113	EFNB3§	0.11 (0.02–0.57)	0.009
C2	Stage	9.88 (1.26–77.27)	0.029	EFNB3	0.10 (0.02–0.60)	0.012
C3	MYCN	3.75 (1.17–12.01)	0.026	EFNB3	0.11 (0.02–0.74)	0.024

Cox regression models were used to assess prognostic significance of variables indicated. HR, Hazard ratio. CI, Confidence interval. 

^*>1 year vs. <1 year. 

^† Stage 3, 4 vs. 1, 2, 4S. 

^‡ Amplified vs. normal. 

^§ Continuous variable.